Biomarker Testing for Actionable Alterations in NSCLC—Perspectives from US-Based Academic and Community Oncologists: A Podcast

The identification of actionable oncogenic driver mutations in patients with non-small cell lung cancer impacts therapy selection, and appropriate therapy administration results in improvements in clinical outcomes. Although biomarker testing for actionable oncogenic driver mutations is recommended...

Descripción completa

Detalles Bibliográficos
Autores principales: Iams, Wade T., Konduri, Kartik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611827/
https://www.ncbi.nlm.nih.gov/pubmed/37779172
http://dx.doi.org/10.1007/s12325-023-02664-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611827/
https://www.ncbi.nlm.nih.gov/pubmed/37779172
http://dx.doi.org/10.1007/s12325-023-02664-1

Ejemplares similares